ESMO 2024: Cora Sternberg video interview about her presentation on event-free survival (EFS) as a surrogate endpoint for overall survival in muscle-invasive bladder cancer.
The INSIDE-PC study provides evidence of the potential of AI systems in medical literature searches on complex clinical questions.
ESMO Congress 2024 - European Society for Medical Oncology Barcellona 13-17 Settembre 2024
In this video Cora Sternberg talks about efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel by disease, volume and risk in the phase three Arasens study.
In this video Dr. Cora Sternberg discusses new developments in the treatment of urothelial carcinoma.
In this interview for UroToday dr. Cora Sternberg presents the latest data and ongoing clinical trials in the context of prostate cancer.
Alicia Morgans speaks with Cora Sternberg about the EV-302 study presented at ESMO 2023. This study marks a significant shift in treating advanced metastatic urothelial cancer, traditionally managed with cisplatin or carboplatin-based chemotherapy.
Urology is one of the specialist surgical branches that has evolved the most in the last twenty years, with continuous and very important innovations in diagnostic-therapeutic terms.
Dr. Cora Sternberg explains the importance of research to find personalized therapies and drugs in the treatment of tumors.
Dr. Cora Sternberg discusses adjuvant therapy for muscle-invasive bladder cancer: new therapies and new standards of care.
Latest studies and updates on prostate cancer, including PROpel, MAGNITUDE and the ARCHES study.
Interview with Dr. Cora Sternberg, Clinical Director of the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York - Presbyterian
Interview with Dr. Cora Sternberg about types of treatment for advanced bladder cancer.
Metastatic castration-resistant prostate cancer (CRPC) is a form of prostate cancer that becomes resistant to treatment with hormone therapy. In this case, the hormonal drug no longer provides benefits and other therapeutic options are necessary.
Interview with Dr. Cora Sternberg about clinical trials and new research on metastatic castration-resistant prostate cancer.
Clinical study on advanced bladder cancer.
Dr. Cora Sternberg discusses data from the Card study in patients with metastatic castration-resistant prostate cancer (mCRPC)
Dr. Sternberg talks about the Prosper study and prostate cancer treatments.
Advanced bladder cancer: Dr. Cora Sternberg talks about advances in recent years and new therapies.
Important results from the Card study for metastatic prostate cancer.
mCRPC, interview with Dr. Cora Sternberg
Dr. Cora Sternberg discusses the results of important studies for bladder cancer
Important results of the ARAMIS Trial, PROSPER Trial and SPARTAN TRIAL for prostate cancer, commented in this interview by Dr. Cora Sternberg.
Dr. Sternberg discusses the results of clinical trials in kidney cancer and bladder cancer.
Dr. Cora Sternberg first talks about urothelial cancer, and the Keynote-45 study on immunotherapy: some data on quality of life, they are really important.
Provide scholarships to Italian oncologists, biologists and other health care members for projects related to Precision Medicine
Help young bright oncologists to establish connections with the EIPM and other International Cancer centers
Provide treatments for Oncology patients that have been identified though Precision Medicine
To create a bridge between Italian patients and this cutting-edge new way to treat cancer
Bring Precision Medicine to Italian Hospitals and Italian patients in collaboration with International Consortia
Create connections between different specialists in Italy such as oncology, pathology, radiology and bioinformatics
Create awareness and education among health professionals and patients about the benefits of Precision Medicine
Making new drugs available to patients will be one important goal of the Foundation